On October 30, 2025, PharmaCyte Biotech, Inc. stockholders approved amendments to the 2022 Equity Incentive Plan, increasing the shares for grants by 2,250,000. Additionally, they authorized share issuance exceeding 20% of the outstanding stock related to convertible preferred stock and warrants.